You are on page 1of 15

SR. NO.

BRANDS
ALOGRACE CREAM
ALOGRACE SYNDET BAR
1

ACNESTAR-20

ARGIPREG SACHET

ARGIPREG PLUS SACHET

ASTHAKIND

ASTHAKIND EXPECTORANT

ASTHAKIND-DX

BIOPREG-F
BIOPREG PLUS
BONAMOST

DIZIKIND-MD

DOLOBAN-AQ

10

DROTIKIND-M

11

DROTIKIND-80

12

DROTIKIND INJ.
ENERBLESS

13

FERIKIND TAB.

14

FERIKIND-M SUSP.

15

FERIKIND PLUS (RF) INJ.

16

FERIKIND SUSP.

17

FERIKIND-S 50/100 INJ.

18

FLOTRIP FORTE

19

FLOTRIP PLUS

20

FLUPIDOL

21

FOLIMUST-D

22

FUL-AID (NF)

23

GESTAKIND-10/ SR

24

GUDCEF RANGE AND GUDCEF-AZ

25

GUDCEF-CV 100

26

GUDCEF PLUS

27

HERPIKIND TAB.

28

HICOPE-25/10

29

ILADAY-10

30

LEVOSURE-500

31

MAXICAL-500

32

MATCH-AR

33

MATCH INJ.

34

MATCH PLUS 4X

35

MEFKIND FORTE

36

MEFKIND SPAS

37

NOBLOK (RF)

38

NUCORT-M

39

NUCFORCE-CD 3

40

NUROSTAR

41

NUROSTAR PLUS

42

OSKAR-DSR
ILADAY DSR
OVABLESS

43

ROXIKIND-150
SCAREND

44

TERBINAFORCE

45

URIKIND-KM 6
URIKIND KM SACHET

46

VENTIDOX-A

47

VENTIDOX-400

48

VENTIDOX-DL
VITAKIND ZIT

49

VERMACT-3/6/12

50

VERMACT PLUS

51

VOMILAST / OD

52

ZESTABOLIN-25/50

53

HAIRBLESS TAB/LOTION

The FDA - assigned


Category A

Adequate and well-controlled studies have


evidence of risk in later trimesters).

Category B
Animal reproduction studies have failed to
pregnant women.

Category C

Animal reproduction studies have shown an


humans,but potential benefits may warran

Category D

There is positive evidence of human fetal r


humans,but potential benefits may warran

Category X

Studies in animals or humans have demon


adverse reaction data from investigational
outweigh potential benefits.

PREGNANCY CATEGORY
X
C
C
C
C
C
C
C
C
B

B
B
B
B
DATA NOT AVAILABLE
DATA NOT AVAILABLE
DATA NOT AVAILABLE
A
C
C
B
B
C
B
C
C
B

DATA NOT AVAILABLE

C
C
C
C
B
C
C
C
C
B

B
C
DATA NOT AVAILABLE
B
C
x
C
C
A
X
-

FDA PREGNANCY CATE


The FDA - assigned pregnancy categories as used in

controlled studies have failed to demonstrate a risk to the fe


ater trimesters).

n studies have failed to demonstrate a risk to the fetus and t

n studies have shown an adverse effect on the fetus and the


al benefits may warrant use of the drug in pregnant women

idence of human fetal risk based on adverse reaction data fr


al benefits may warrant use of the drug in pregnant women

or humans have demonstrated fetal abnormalities and/or the


ta from investigational or marketing experience, and the ris
benefits.

COMMENTS

L PREPATAION , SO CAN BE GIVEN . It's Ingredients Category is not


by FDA

L PREPATAION , SO CAN BE GIVEN . It's Ingredients Category is not


by FDA

ne is a nutritional supplement, It's Category is not decided by FDA t


s safe in Pregnancy. References prove safety and positive outcome

redients Category is not decided by FDA, But part of B Complex wh


safe in Pregnancy. References prove safety and positive outcomes

ngredients Category is not decided by FDA. References prove safety


positive outcomes
Shall be taken only on discretion of doctor

USED AT THE TIME OF DELIVERY FOR CERVICAL DILATION

ngredients Category is not decided by FDA. References prove safety


positive outcomes

NO STUDY SUGGESTS USE IN PREGNANCY


NO STUDY SUGGESTS USE IN PREGNANCY

REFERENCES PROVE SAFETY AND POSITIVE OUTCOMES


CYANOCOBALAMIN IS CATEGORY C DRUG
REFERENCES PROVE SAFETY AND POSITIVE OUTCOMES

DATA AVAILABLE REGARDING SAFETY OF ILAPRAZOLE IN PREGNAN

emisinin derivatives are Category B Drugs, while No data available


Lumufentrine. Match and Match-AR can be given in Pregnancy

ONLY IF USED TOPICALLY AS SUPPOSITORIES.

OT REQUIRED DURING PREGNANCY, SHOULD BE STOPPED WHEN TH


PREGNANCY IS DETECTED

ngredients Category is not decided by FDA. References prove safety


positive outcomes

BUT CAN BE GIVEN SAFELY

ngredients Category is not decided by FDA. References prove safety


positive outcomes

Should be avoided

OSITOL IS CATEGORY C DRUG(TABLET) AND MINOXIDIL IS CATEGOR


DRUG(LOTION)

Y CATEGORIES

used in the Drug Formulary are as follows:

to the fetus in the first trimester of pregnancy (and there is

tus and there are no adequate and well-controlled studies in

and there are no adequate and well-controlled studies in


women despite potential risks.

n data from investigational or marketing experience or stud


women despite potential risks.

nd/or there is positive evidence of human fetal risk based on


d the risks involved in use of the drug in pregnant women c